BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Over 200 Studies Awarded to India-Based CRO Max Neeman International


1/26/2011 9:14:22 AM

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2011 /PRNewswire/ -- Max Neeman International, India's premier CRO, has quadrupled the amount of clinical trials awarded since 2007 and reached the milestone of over 200 in 2010. Per CEO, Dr. Ajoy Kumar, "Focused areas of specialty, unique offerings, customer service and consistent growth in response to customer demand, are the cumulative factors which helped us to achieve this number."

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO )

This milestone depicts Max Neeman's strong growth in only 3 years and testifies to the company's philosophy and work ethic, successfully completing a number of trials for global sponsors across a wide range of therapeutic areas. The company boasts a 98% patient retention rate and has met target enrollments by the deadline while facing challenges of: conducting studies involving tough protocols, gigantic enrollment targets and stringent regulatory requirements.

Over 200 trials enrich the Max Neeman experience, having dealt with various therapeutic segments and unexplored areas of nutraceuticals, biosimilars and medical devices. In response to increased client demand over the decade, Max Neeman expanded its medical writing, data management, central lab and pharmacy services as well. Thus in its constant quest to become a truly world class organization, Max Neeman continues to deliver service excellence with the highest ethical standards to its customers in developing drugs and devices that have the potential to restore health and save lives.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company has 6 regional offices and 175 sites across 31 cities. Contact Donald Swankie, Vice President USA via email to donald.swankie@neeman-medical.com or call +1.919.424.3345. www.neeman-medical.com

About Max Healthcare

Also part of the Max India group, Max Healthcare is part of a leading chain of hospitals in India. Its state of the art infrastructure and most advanced technologies makes it one of the best hospitals in the country. www.maxhealthcare.in

SOURCE Max Neeman International



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES